Ascendis Pharma Q2 2026: Revenue Soars 115%, Net Profit €207M on PRV Sale and Deferred Tax Recognition
ASND sits 40% above its 52-week low of $186.054.
Summary
Ascendis Pharma reported Q2 2026 revenue of €339.3M (up 115% YoY) and net profit of €207.0M, driven by YORVIPATH growth, YUVIWEL launch, PRV sale, and deferred tax recognition. Convertible notes were fully redeemed, and the $120M buyback was completed.
Key Events · Earnings and Guidance · ASND
-
Revenue More Than Doubles
Q2 2026 revenue reached €339.3M, up 115% from €158.0M in Q2 2025. H1 revenue was €585.9M vs €259.0M. YORVIPATH led with €252.1M in Q2, up 145% YoY.
-
Net Profit Swings to €207M
Q2 net profit was €207.0M vs a €38.9M loss last year. H1 net profit was €836.3M, boosted by a €679.6M deferred tax asset recognition and €158.1M PRV sale income.
-
Convertible Notes Fully Redeemed
On May 6, 2026, all $575M of 2.25% convertible notes due 2028 were converted into 3,635,813 ordinary shares, eliminating €719.4M of borrowings and derivative liabilities from the balance sheet.
-
PRV Sale Adds €158M
The Rare Pediatric Disease Priority Review Voucher from YUVIWEL's approval was sold for $187.5M, contributing €158.1M to other operating income in Q2.
Analysis · ASND · Life Sciences
A transformative quarter for Ascendis Pharma. Revenue more than doubled year-over-year to €339.3 million, driven by YORVIPATH's global expansion and the U.S. launch of YUVIWEL. Net profit swung to €207.0 million from a €38.9 million loss a year ago, boosted by the €158.1 million sale of a Rare Pediatric Disease Priority Review Voucher and a €679.6 million deferred tax asset recognition. The company also eliminated $575 million of convertible debt through conversion, strengthening the balance sheet. These results confirm the commercial ramp of its endocrinology rare disease franchise and mark a clear inflection toward sustained profitability.
At the time of this filing, ASND was trading at $260.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.9B. The 52-week trading range was $186.05 to $282.15. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.